SG59931A1 - Stem cell factor - Google Patents

Stem cell factor

Info

Publication number
SG59931A1
SG59931A1 SG1996001817A SG1996001817A SG59931A1 SG 59931 A1 SG59931 A1 SG 59931A1 SG 1996001817 A SG1996001817 A SG 1996001817A SG 1996001817 A SG1996001817 A SG 1996001817A SG 59931 A1 SG59931 A1 SG 59931A1
Authority
SG
Singapore
Prior art keywords
scf
dna sequence
stem cell
cell factor
biological activity
Prior art date
Application number
SG1996001817A
Inventor
Kristztina M Zsebo
Sidney Vaughn Suggs
Robert A Bosselman
Francis Hall Martin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1990/005548 external-priority patent/WO1991005795A1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG59931A1 publication Critical patent/SG59931A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier

Abstract

Non-naturally occurring polypeptide (I) is claimed, whose aminoacid sequence is similar enough to naturally-occurring stem cell factor (SCF) to give it the same haematopoietic biological activity. (I) is produced by eukaryotic or prokaryotic expression of an exogeneous DNA sequence, and has in vivo and in vitro biological activity. Also claimed are a DNA sequence encoding (I), a host transformed with the DNA sequence, a process for producing and recoverng SCF, a DNA sequence encoding a human SCF analogue, an antibody that binds SCF, a compsn.; of (I) with a water-soluble polymer, a method of preparing the above compsn. and a method of transfecting early haematopoietic stem cells. Routes of administration are e.g. parenteral, pulmonary, nasal and oral.
SG1996001817A 1989-10-16 1990-10-04 Stem cell factor SG59931A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42238389A 1989-10-16 1989-10-16
US53719890A 1990-06-11 1990-06-11
US57361690A 1990-08-24 1990-08-24
PCT/US1990/005548 WO1991005795A1 (en) 1989-10-16 1990-09-28 Stem cell factor
US58970190A 1990-10-01 1990-10-01

Publications (1)

Publication Number Publication Date
SG59931A1 true SG59931A1 (en) 1999-02-22

Family

ID=27503703

Family Applications (2)

Application Number Title Priority Date Filing Date
SG1996002213A SG43009A1 (en) 1989-10-16 1990-10-04 Stem cell factor
SG1996001817A SG59931A1 (en) 1989-10-16 1990-10-04 Stem cell factor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG1996002213A SG43009A1 (en) 1989-10-16 1990-10-04 Stem cell factor

Country Status (11)

Country Link
US (3) US6218148B1 (en)
EP (4) EP0676470A1 (en)
CN (2) CN1289526C (en)
AT (2) ATE194651T1 (en)
CZ (3) CZ286303B6 (en)
DE (2) DE69033584T2 (en)
DK (1) DK0423980T3 (en)
GR (1) GR3034559T3 (en)
HK (1) HK1010397A1 (en)
SG (2) SG43009A1 (en)
SK (2) SK281487B6 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759215B1 (en) * 1989-10-16 2004-07-06 Amgen Inc. Method of preparing human stem cell factor polypeptide
WO1992000376A1 (en) * 1990-06-25 1992-01-09 Immunex Corporation Mast cell growth factor
US20030125519A1 (en) 1990-08-27 2003-07-03 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
US20050276784A1 (en) * 1990-08-27 2005-12-15 Solan-Kettering Institute For Cancer Research Ligand for the c-kit receptor and methods of use thereof
US5767074A (en) * 1990-08-27 1998-06-16 Sloan-Kettering Institute For Cancer Research Compositions of soluble C-kit ligand and hematopoietic factors
DE4224050A1 (en) * 1991-07-31 1993-02-04 Hoffmann La Roche LOCAL KIT LIGANDS
US6001803A (en) * 1992-04-23 1999-12-14 Sloan-Kettering Institute For Cancer Research Composition of c-kit ligand, GM-CSF, and TNF-α and method of use
JP3750819B2 (en) * 1992-04-23 2006-03-01 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ Ligand for C-KIT receptor and method of use thereof
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US5525708A (en) * 1994-03-28 1996-06-11 Cytomed, Inc. Covalent dimer of kit ligand
CA2203372C (en) * 1994-11-04 2008-03-11 Applied Research Systems Ars Holding N.V. Human scf, a splice variant thereof, its pharmaceutical use
US5824789A (en) * 1995-06-07 1998-10-20 Systemix, Inc. Human growth factors, nucleotide sequence encoding growth factors, and method of use thereof
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US6184200B1 (en) 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
ATE432085T1 (en) 1995-10-04 2009-06-15 Immunex Corp STIMULATION FACTOR FOR DENDRITES
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5885962A (en) * 1996-04-05 1999-03-23 Amgen Inc. Stem cell factor analog compositions and method
EP0953354A4 (en) 1996-08-13 2002-10-23 Fujisawa Pharmaceutical Co Hematopoietic stem cell proliferating agents
US5969105A (en) * 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
JPH10158188A (en) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd Composition for treating cornea
CA2395236A1 (en) * 1999-12-23 2001-07-05 Universite De Geneve Basolateral sorting signal and inhibitors thereof
AU2001276831A1 (en) 2000-06-22 2002-01-02 Rxkinetix, Inc. Delivery vehicle composition and methods for delivering antigens and other drugs
EP1351696A4 (en) 2000-06-26 2004-04-14 Rxkinetix Inc Composition for delivery of hematopoietic growth factor
CA2449978A1 (en) * 2001-06-15 2002-12-27 Johns Hopkins Singapore Pte Ltd Biofunctional fibers
US20030124091A1 (en) * 2001-10-26 2003-07-03 Large Scale Biology Corporation Endothelial cell derived hematopoietic growth factor
CN100422334C (en) * 2001-11-27 2008-10-01 内克西特股份有限公司 Production of eukaryotic proteins and nucleic acid molecules in c. elegans
US7994125B2 (en) 2003-02-14 2011-08-09 Istituto Superiore Di Sanita Stem cell factor for preventing chemotherapy-induced depletion of blood cells
CN100345971C (en) * 2003-07-14 2007-10-31 第二军医大学免疫学研究所 Recombinant human stem cell factor prokaryote expression vector, engineering bacteria and its preparation method
EP1697399B1 (en) 2003-12-12 2016-11-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
EP1778865A1 (en) * 2004-06-23 2007-05-02 Epigenomics AG Methods and nucleic acids for the detection of metastasis of colon cell proliferative disorders
CN1993460A (en) * 2004-07-12 2007-07-04 索林集团意大利有限公司 Device and method for cultivating human cell
ATE544463T1 (en) 2004-11-05 2012-02-15 Univ Northwestern USE OF SCF AND G-SCF IN THE TREATMENT OF BRAIN SCHEMIA AND NEUROLOGICAL DISORDERS
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc Self-buffering protein formulations
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
AU2006315601A1 (en) * 2005-11-14 2007-05-24 Enterprise Partners Venture Capital Stem cell factor therapy for tissue injury
WO2007102814A2 (en) * 2006-03-07 2007-09-13 Regenetech, Inc. Recombinant mammalian molecules and method for production thereof
WO2007109583A2 (en) 2006-03-17 2007-09-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
RU2493252C2 (en) * 2006-03-24 2013-09-20 Чилдрен'З Медикал Сентер Корпорейшн Method to stimulate expansion of haematopoietic stem cells
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
EP1872790A1 (en) 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft New formulation for increasing bioavailability of neurturin
JP5426389B2 (en) 2006-10-20 2014-02-26 チルドレンズ メディカル センター コーポレーション Methods for enhancing tissue regeneration
US20090053786A1 (en) 2007-07-09 2009-02-26 Yung-Hsiang Kao Prevention of disulfide bond reduction during recombinant production of polypeptides
US20110206781A1 (en) * 2008-05-28 2011-08-25 Zon Leonard I Method to modulate hematopoietic stem cell growth
WO2010055900A1 (en) 2008-11-14 2010-05-20 ディナベック株式会社 Method for producing dendritic cells
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US9056085B2 (en) 2009-02-03 2015-06-16 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
CN105646709A (en) 2011-01-10 2016-06-08 密执安大学评议会 Stem cell factor inhibitor
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
EP3785767A1 (en) 2011-12-02 2021-03-03 Fate Therapeutics, Inc. Enhanced stem cell composition
WO2014150602A1 (en) 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
US9889451B2 (en) 2013-08-16 2018-02-13 ADA-ES, Inc. Method to reduce mercury, acid gas, and particulate emissions
LT6161B (en) 2013-09-27 2015-06-25 Uab Profarma Fused proteins of granulocyte colony-stimulating factor with other partners of growh factor, preferably with stem cell factor, and method of preparation thereof
JP6383216B2 (en) * 2014-08-08 2018-08-29 シスメックス株式会社 Blood analysis method, blood analysis apparatus and program
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CN105985424B (en) * 2015-01-30 2019-08-23 苏州方舟生物医药有限公司 A kind of stem cell factor functionality peptide fragment and its application
CN105749252A (en) * 2016-04-29 2016-07-13 南方医科大学 Application of IL-9 serving as medicine for treating thrombocytopenia
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN108541660A (en) * 2018-04-24 2018-09-18 上海动物园 Veterinary method, animal raising device and its fermentation bed
EP3844278A4 (en) * 2018-08-27 2022-05-25 North Carolina State University Targeting kit with splice switching oligonucleotides to induce apoptosis of mast cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695542A (en) * 1983-10-04 1987-09-22 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS62223126A (en) 1986-03-25 1987-10-01 Sankyo Co Ltd Growth factor for blood stem cell
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1

Also Published As

Publication number Publication date
US6218148B1 (en) 2001-04-17
CN1051937A (en) 1991-06-05
HK1010397A1 (en) 1999-06-17
CN1075078C (en) 2001-11-21
DE69033584D1 (en) 2000-08-17
CN1306007A (en) 2001-08-01
EP0423980B1 (en) 2000-07-12
US6207417B1 (en) 2001-03-27
EP1241258A2 (en) 2002-09-18
SG43009A1 (en) 1997-10-17
CZ48897A3 (en) 2000-01-12
CZ49097A3 (en) 2000-01-12
GR3034559T3 (en) 2001-01-31
CZ286304B6 (en) 2000-03-15
DE69033584T2 (en) 2001-03-08
CZ286303B6 (en) 2000-03-15
SK500890A3 (en) 2001-04-09
SK98199A3 (en) 2001-04-09
EP1241258A3 (en) 2003-12-10
DK0423980T3 (en) 2000-10-09
EP0992579B1 (en) 2008-08-06
EP0676470A1 (en) 1995-10-11
CN1289526C (en) 2006-12-13
EP0992579A1 (en) 2000-04-12
ATE403713T1 (en) 2008-08-15
CZ286305B6 (en) 2000-03-15
CZ49197A3 (en) 2000-01-12
EP0423980A1 (en) 1991-04-24
ATE194651T1 (en) 2000-07-15
SK281484B6 (en) 2001-04-09
DE69034258D1 (en) 2008-09-18
SK281487B6 (en) 2001-04-09
US6207802B1 (en) 2001-03-27

Similar Documents

Publication Publication Date Title
HK1010397A1 (en) Stem cell factor
ZA943464B (en) Vascular endothelial growth factor 2
HK1008400A1 (en) Genetic modification of endothelial cells
WO1988002406A3 (en) Methods of regulating metabolic stability of proteins
NO174351C (en) Process for producing human insulin precursor, as well as DNA sequence and vector for use of the method
EP0859833A4 (en) Recombinant hepatitis c virus rna replicase
DE68918867D1 (en) Mutants of the hiv-1 coat protein with missing hypervariable domains.
CA2038398A1 (en) Dna encoding a growth factor specific for epithelial cells
WO1989009829A3 (en) Methods of generating desired amino-terminal residues in proteins
EP0759067A4 (en) Transforming growth factor alpha h1
EP0424416A4 (en) Acid-labile subunit (als) of insulin-like-growth factor (igf) binding protein complex
WO2000034474A3 (en) Growth factor homolog zvegf3
ES8506347A1 (en) DNA sequences, recombinant DNA molecules and processes for producing human interleukin two-like polypeptides.
MY104910A (en) New derivatives of human/bovine4 basic fibroblast growth factor.
Kurobe et al. Synthesis and secretion of an epidermal growth factor (EGF) by human fibroblast cells in culture
NO984491L (en) SCF analog preparations and methods for their preparation
ES2004099A6 (en) Use of biologically active polypeptides and compositions containing them.
ES8605296A1 (en) Recominant factor VIII-R.
ZA892518B (en) Method for the in-vivo production and testing of proteins by recombinant gene expression in selected host-cells
IL91475A0 (en) Production of gonadotropin superagonists by recombinant dna methods and said super agonists produced thereby
ATE116366T1 (en) METHOD FOR PRODUCING A HUMAN ''NEUTROPHIL CHEMOTACTIC FACTOR'' POLYPEPTIDE.
ES2033212A6 (en) Ancrod proteins, their production and use.
HUP9800520A2 (en) Gene expression in mammalian cells
WO1990012807A3 (en) Purified, highly specific antibodies against gene products including retinoblastoma and method
O'Donnell et al. Production of platelet-derived growth factorlike protein (s) by a human carcinoma cell line